newsfilter
← Latest News
PR Newswire·

Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

-- FDA has provided clearance to the company to continue dosing patients who have already undergone lymphodepletion -- REDWOOD CITY, Calif., June 19, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology